What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million

PTC Therapeutics' chief technical operations officer sold 2,464 shares under a routine pre-established trading plan, generating $222,376. The insider retains substantial holdings of 63,198 shares plus 45,036 derivative securities. The sale is routine equity compensation management and not indicative of concern, as the company demonstrates strong commercial momentum with Q1 product revenue of $225.6 million, driven by PKU drug Sephience's $124.6 million in sales (up 36% quarterly). Management raised full-year product revenue guidance to $750-850 million.